Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elritercept in Myelofibrosis
NCT05037760Phase 2Recruiting
- Sponsor
- Takeda
- Start
- Dec 2021
- Primary completion
- Feb 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 7
01
Overview
Phase 2, open-label trial of elritercept in myelofibrosis (MF) and anemia, sponsored by Takeda. Primary endpoint: Number of Participants with Adverse Events, Dose Limiting Toxicities, Severe Adverse Events and Serious Adverse Events at 8 years. Started Dec 2021; status: recruiting.
02
Drugs
elritercept
03
Conditions
myelofibrosis (MF)anemia
Beyond the preview
Go deeper on NCT05037760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05037760.